300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
CleanTech
InsurTech
Oil and Gas
Retail
Payments
Film
Fitness
Marketplace
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
Facebook
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Renewable Energy
Software
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Climate
Beauty
Fashion
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
LGBT
Cannabis
Celebrity
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Togo
Nigeria
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Oman
Romania
Poland
Puerto Rico
China
Cameroon
Guernsey
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Satish Jindal, General Partner at Advent Life Sciences

Satish Jindal

General Partner @ Advent Life Sciences

Cambridge, United States

Satish Jindal is a General Partner at Advent Life Sciences. He previously worked at Antolrx Pharmaceuticals as a Board Member and Co-founder. Satish Jindal attended the Massachusetts Institute of Technology.

Total investments:
2
Last investment:
Lead investor:
0%

Last updated:

Industries Satish Jindal invests in

BiotechnologyBiopharmaLife ScienceTherapeutics

Stages Satish Jindal invests in

SeedSeries A

Countries Satish Jindal invests in

United Kingdom

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 2 (100%)
  • Biopharma 1 (50%)
  • Life Science 1 (50%)
  • Therapeutics 1 (50%)

Stage

  • Seed 1 (50%)
  • Series A 1 (50%)

Investments

CompanyDescriptionRoundLinks
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. $31M / Seed / Oct 24, 2024
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. $7.5M / Series A / Apr 07, 2020

Co-Investors

Advent Life Sciences

About Advent Life Sciences

VC Fund · London, United Kingdom

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Advent Life Sciences Contacts

NameEmailPhoneSocials
Andrew J Wood
Andrew J Wood Venture Partner
Dale Pfost
Dale Pfost General Partner
Kaasim Mahmood
Kaasim Mahmood General Partner
Satish Jindal
Satish Jindal General Partner
Shahzad Malik
Shahzad Malik General Partner

Sign up to unlock verified contacts

Unlock Contacts

See all 11 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
CleanTech
InsurTech
Oil and Gas
Retail
Payments
Film
Fitness
Marketplace
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
Facebook
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Renewable Energy
Software
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Climate
Beauty
Fashion
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
LGBT
Cannabis
Celebrity
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Togo
Nigeria
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Oman
Romania
Poland
Puerto Rico
China
Cameroon
Guernsey
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Satish Jindal invest in?

Satish Jindal invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Satish Jindal?

Public channels for Satish Jindal include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Satish Jindal last invest?

The most recent investment recorded for Satish Jindal closed in Oct 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Satish Jindal Satish Jindal Find email